Protalix BioTherapeutics (PLX) Gross Profit (2010 - 2026)

Protalix BioTherapeutics' Gross Profit history runs 17 years deep, the most recent figure standing at $29.6 million for Q1 2026.

• On a quarterly basis, Gross Profit rose 1432.49% year-over-year to $29.6 million in Q1 2026; TTM through Mar 2026 was $53.4 million, a 78.93% increase from a year earlier, with the FY2025 full-year figure at $25.8 million, down 11.45% from the prior year.
• Gross Profit grew to $29.6 million in Q1 2026 per PLX's latest filing, from $4.5 million in the prior quarter.
• Across five years, Gross Profit topped out at $29.6 million in Q1 2026 and bottomed at $1.1 million in Q1 2024.
• The 5-year median for Gross Profit is $6.5 million (2023), against an average of $9.1 million.
• Across the five-year window, Gross Profit plunged 86.11% in 2024 and surged 1432.49% in 2026, its largest moves.
• Year by year, Gross Profit stood at $6.2 million in 2022, then plunged by 73.79% to $1.6 million in 2023, then soared by 779.26% to $14.3 million in 2024, then plunged by 68.58% to $4.5 million in 2025, then soared by 557.85% to $29.6 million in 2026.
• Per Business Quant, the three latest PLX Gross Profit figures stand at $29.6 million (Q1 2026), $4.5 million (Q4 2025), and $9.5 million (Q3 2025).